Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Trial ID or NCT#
The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of PCI-32765 in this population.
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office
About this Clinical Trial
Your Message Will Go ToCancer Clinical Trials Office
To:Cancer Clinical Trials Office
Go Back To The Trial